文献速递妇产影像介入MR

缩宫素与米索前列醇联合双氯芬酸在MR-HIFU治疗症状性子宫肌瘤前的准备:前瞻性队列研究

Oxytocin and Misoprostol With Diclofenac in the Preparation for Magnetic Resonance-Guided High-Intensity Ultrasound Treatment of Symptomatic Uterine Fibroids: A Prospective Cohort Study.
PubMed 文献 · Ultrasound Med Biol · 2021-03-28

该前瞻性队列研究纳入247例症状性子宫肌瘤女性,评估经阴道米索前列醇和静脉缩宫素预处理对MR-HIFU术后无灌注体积(NPV)、声照射时间和6个月肌瘤体积变化的影响。结果显示药物预处理组NPV高于未用药组(米索前列醇/双氯芬酸组85.2%±15.1%,缩宫素组76.8%±20.7%,对照组61.9%±25.8%),声照射时间缩短,但6个月肌瘤体积变化组间无显著差异。作者认为血管收缩药物可能提高MR-HIFU有效性,但需随机对照试验验证。

要点

  • 药物预处理可提高MR-HIFU术后即刻NPV,米索前列醇/双氯芬酸组最高。
  • 药物预处理可缩短声照射时间,米索前列醇/双氯芬酸组平均80分钟。
  • 6个月肌瘤体积变化组间无显著差异,需RCT验证真实效应。

核心结论

  • 药物预处理(缩宫素或米索前列醇/双氯芬酸)可提高MR-HIFU治疗子宫肌瘤的即刻NPV并缩短声照射时间,但6个月肌瘤体积变化无显著组间差异。

研究设计与样本

  • 前瞻性队列研究,纳入247例有症状子宫肌瘤的育龄女性,根据妇科检查和MRI扫描分组:128例符合MR-HIFU且未用药(对照组),57例接受米索前列醇/双氯芬酸预处理,62例接受缩宫素预处理。

关键影像表现/征象

  • MR-HIFU术后即刻平均NPV:对照组61.9%±25.8%,缩宫素组76.8%±20.7%,米索前列醇/双氯芬酸组85.2%±15.1%。
  • 平均声照射时间:对照组120分钟±56.4%,缩宫素组111分钟±45.4%,米索前列醇/双氯芬酸组80分钟±47.7%。
  • 6个月肌瘤体积变化:对照组37.4%±27.5%(n=40),缩宫素组45.8%±31%(n=25),米索前列醇/双氯芬酸组33.4%±23.2%(n=19),组间无显著差异。

临床应用与阅片要点

  • MR-HIFU治疗症状性子宫肌瘤前,可考虑使用缩宫素或米索前列醇/双氯芬酸预处理以提高NPV和缩短治疗时间。
  • 米索前列醇/双氯芬酸组即刻NPV最高,但6个月体积变化最低,需注意长期疗效与即刻NPV不一定平行。

局限性

  • 研究为前瞻性队列设计,非随机对照,可能存在选择偏倚。
  • 6个月随访样本量减少(对照组40例、缩宫素组25例、米索前列醇/双氯芬酸组19例),可能影响长期结局的统计效能。
  • 作者指出需要随机对照试验来估计血管收缩剂对MR-HIFU的真实效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Uterine fibroids (UFs) are very common benign tumors of the female reproductive tract. According to recent reports, magnetic resonance-guided high-intensity ultrasound (MR-HIFU) appears to be a well-tolerated and efficient treatment option for UFs. However, MR-HIFU still presents several limitations. The treatment is rarely associated with achieving complete non-perfused volume (NPV). Not all patients are qualified for a final procedure, and selected women obtain very good results in such treatment. The primary objective of this experimental study was to assess the effect of transvaginal misoprostol and intravenous oxytocin preparation on UF volume change, sonication time and NPV after MR-HIFU procedure in women of reproductive age with symptomatic UFs. Secondary outcomes included the effect on the peri-procedural effectiveness of misoprostol and oxytocin. This study enrolled 247 women with symptomatic UFs; based on gynecologic examinations and magnetic resonance imaging (MRI) scans, 128 women qualified for MR-HIFU without pharmacologic treatment, 57 women qualified for the misoprostol/diclofenac group and 62 women qualified for the oxytocin group. Pharmacologic pre-treatment improved NPV compared with non-pharmacologic treatment (average NPV: controls 61.9% ± 25.8%; oxytocin 76.8% ± 20.7%; misoprostol/diclofenac 85.2% ± 15.1%; average sonication time: controls 120 min ± 56.4%; oxytocin 111 min ± 45.4%; misoprostol/diclofenac 80 min ± 47.7%). Statistical analysis did not reveal significant intergroup differences in UF volume changes after 6 mo (controls: n = 40, 37.4% ± 27.5%; oxytocin n = 25, 45.8% ± 31%; misoprostol/diclofenac n = 19, 33.4% ± 23.2%). The misoprostol/diclofenac group, which achieved the highest NPV immediately after the MR-HIFU procedure, was characterized by the lowest UF volume change percentages 6 mo later. The administration of vasoconstrictor drugs (oxytocin and misoprostol/diclofenac) to support MR-HIFU in UF treatment is a new issue that may improve the total effectiveness of this method. Randomized controlled trials are necessary to estimate the real effect of vasoconstrictors on MR-HIFU.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Łoziński T, Ludwin A, Filipowska J, et al. Oxytocin and Misoprostol With Diclofenac in the Preparation for Magnetic Resonance-Guided High-Intensity Ultrasound Treatment of Symptomatic Uterine Fibroids: A Prospective Cohort Study. Ultrasound Med Biol. 2021. PMID: 33785226. doi:10.1016/j.ultrasmedbio.2021.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。